VistaGen Therapeutics, Inc. (VTGN)
Automate Your Wheel Strategy on VTGN
With Tiblio's Option Bot, you can configure your own wheel strategy including VTGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTGN
- Rev/Share 0.0202
- Book/Share 1.8557
- PB 0.3123
- Debt/Equity 0.0281
- CurrentRatio 5.7853
- ROIC -0.9552
- MktCap 18991795.0
- FreeCF/Share -1.4852
- PFCF -0.3577
- PE -0.3329
- Debt/Assets 0.023
- DivYield 0
- ROE -0.9065
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VTGN | Jefferies | Buy | Hold | -- | $0.9 | Dec. 17, 2025 |
| Downgrade | VTGN | Maxim Group | Buy | Hold | -- | -- | Dec. 17, 2025 |
| Downgrade | VTGN | Stifel | Buy | Hold | -- | $1 | Dec. 17, 2025 |
| Downgrade | VTGN | William Blair | Outperform | Market Perform | -- | -- | Dec. 17, 2025 |
News
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: February 03, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. So what: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Class Action Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: January 29, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Published: January 28, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options
Read More
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Vistagen Therapeutics Class Action Lawsuit?
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Published: January 27, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. ("Vistagen" or …
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: January 22, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
Published: January 22, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN)? Did you purchase your shares between April 1, 2024 and December 16, 2025, inclusive?
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Published: January 22, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: …
Read More
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors
Published: January 22, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vistagen Therapeutics, Inc., (“Vistagen” or the "Company") (NASDAQ: VTGN) investors of a class action on behalf of investors that bought securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). Vistagen investors have until March 16, 2026 to file a lead plaintiff motion.
Read More
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky
Published: January 21, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025.
Read More
VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm
Published: January 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: January 19, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 19, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Vistagen securities between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period").
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: January 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: January 19, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: January 16, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $VTGN--VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (VTGN)
Published: January 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) securities between April 1, 2024 and December 16, 2025.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Vistagen Therapeutics, Inc. (VTGN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: January 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen's Phase 3 PALISADE-3 trial study of fasedienol.
Read More
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Published: December 17, 2025 by: Benzinga
Sentiment: Negative
Vistagen Inc. (NASDAQ: VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro.
Read More
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Vistagen Therapeutics' intranasal pherine drugs target nose-to-brain circuits. This taps into neuropsychiatric, women's health, and oncology indications. Their lead asset is Fasedienol, which is in Phase 3 for SAD. Its PALISADE-3 data may enable a possible NDA submission during 2026. The rest of VTGN's pipeline includes Itruvone, PH80, and PH284. However, I believe VTGN's tight runway will force them to prioritize Fasedienol's R&D.
Read More
Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief Operating Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K.
Read More
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Program evaluating fasedienol for acute treatment of social anxiety disorder (SAD). The Company's PALISADE-.
Read More
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company's poster presentations will explore the age of onset of social anxiety dis.
Read More
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - Chief Executive Officer and Director Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants John Boyle - William Blair Operator Good day. Thank you for standing by.
Read More
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Negative
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
Read More
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update. “We had a very productive quarter, with both PALISADE-3 and PALISADE-4 advancing towards expected top-line.
Read More
About VistaGen Therapeutics, Inc. (VTGN)
- IPO Date 2011-06-21
- Website https://www.vistagen.com
- Industry Biotechnology
- CEO Shawn K. Singh
- Employees 48